drugset / Trial / NCT01886599

Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease

NCT01886599

Phase 1 Completed 48 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-label

Summary

The purpose of the study is to determine how Asunaprevir is handled by the body of subjects with kidney disease compared with subjects with normal kidney function

Timeline

Start
2012-11
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Asunaprevir Small molecule 100 mg Oral